5AM Venture Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

5AM Venture Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-462,286	Closed	-$13.7M	–	27
2023 Q3	$13.7M	Sell	462,286 -400,000	-46%	-$8.24M	3.96%	6
2023 Q2	$15.5M	Hold	862,286	–	–	3.87%	7
2023 Q1	$13.8M	Hold	862,286	–	–	3.54%	5
2022 Q4	$15.8M	Hold	862,286	–	–	4.24%	8
2022 Q3	$16.9M	Hold	862,286	–	–	3.24%	10
2022 Q2	$16.1M	Hold	862,286	–	–	3.98%	11
2022 Q1	$18.9M	Hold	862,286	–	–	4.13%	9
2021 Q4	$24.5M	Sell	862,286 -500,000	-37%	-$12.3M	4.6%	9
2021 Q3	$28.7M	Hold	1,362,286	–	–	5.82%	9
2021 Q2	$25.7M	Hold	1,362,286	–	–	6.46%	6
2021 Q1	$20.8M	Hold	1,362,286	–	–	3.75%	8
2020 Q4	$19.2M	Hold	1,362,286	–	–	6.47%	7
2020 Q3	$21.3M	Hold	1,362,286	–	–	5.61%	8
2020 Q2	$23.9M	Sell	1,362,286 -500,000	-27%	-$8.52M	5.23%	8
2020 Q1	$27.4M	Sell	1,862,286 -500,000	-21%	-$10.2M	8.48%	4
2019 Q4	$59.3M	Buy	+2,362,286	New	+$45M	12.75%	3

Other funds holding CRNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

5AM Venture Management's CRNX Position: Q4 2023 in Review

5AM Venture Management sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2023, closing a stake of 462,286 shares — an estimated $13.7M sold.

5AM Venture Management first reported a position in CRNX in Q4 2019 and held it in 16 quarters. The position peaked at $59.3M in Q4 2019. 181 funds tracked by Wall St. Rank hold CRNX as of Q4 2023.

5AM Venture Management reported no remaining Crinetics Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
5AM Venture Management sold 462,286 Crinetics Pharmaceuticals shares in Q4 2023, an estimated $13.7M.
5AM Venture Management first reported a position in Crinetics Pharmaceuticals in Q4 2019 and held it in 16 quarters.
5AM Venture Management's Crinetics Pharmaceuticals position peaked at $59.3M in Q4 2019.
181 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2023.

Based on 5AM Venture Management's 13F filing for Q4 2023, filed 14 Feb 2024.